Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines

Virology

Volumn 223, Issue 1, 1996, Pages 29-40

  Floettmann, J E ^a   Ward, K ^a,b   Rickinson, A B ^a,b   Rowe, M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; TETRACYCLINE; VIRUS PROTEIN;

ARTICLE; B LYMPHOCYTE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL;

EID: 0030245723     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0452     Document Type: Article

References (49)

1. Åman, P., Rowe, M., Kai, C., Finke, J., Rymo, L., Klein, E., and Klein, G. (1990). Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines. Int. J. Cancer 45, 77-82.
2. Arvanitakis, L., Yaseen, N., and Sharma, S. (1995). Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-β1-mediated growth inhibition in EBV-positive B cells. J. Immunol. 155, 1047-1056.
3. Baichwal, V. R., and Sugden, B. (1987). Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus. J. Virol. 61, 866-875.
4. Baichwal, V. R., and Sugden, B. (1988). Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2, 461-467.
5. Ben-Bassat, H., Goldblum, N., Mitrani, S., Goldblum, T., Yoffey, J. M., Cohen, M. M., Bentwitch, Z, Ramot, B., Klein, E., and Klein, G. (1977). Establishment in culture of a new type of lymphocyte from a "Burkitt-like" lymphoma (line D.G.-75). Int. J. Cancer 19, 27-33.
6. Cohen, J. I., Wang, F., Mannick, J., and Kieff, E. (1989). Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA 86, 9558-9562.
7. Cuomo, L., Ramquist, T., Trivedi, P., Wang, F., Klein, G., and Masucci, M. G. (1992). Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorgenicity of an EBV-negative Burkitt Lymphoma line. Int. J. Cancer 51, 949-955.
8. Cuomo, L., Trivedi, P., Wang, F., Winberg, G., Klein, G., and Masucci, M. (1990). Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures. Eur. J. Immunol. 20, 2293-2299.
9. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547-5551.
10. Grasser, F. A., Haiss, P., Gottel, S., and Mueller-Lantzsch, N. (1991). Biochemical characterization of Epstein-Barr virus nuclear antigen 2A. J. Virol. 65, 3779-3788.
11. Gregory, C. D., Dive, C., Henderson, S., Smith, C., Williams, G. T., Gordon, J., and Rickinson, A. B. (1991). Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349, 612-614.
12. Gregory, C. D., Rowe, M., and Rickinson, A. B. (1990). Different Epstein-Barr virus (EBV)-B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J. Gen. Virol. 71, 1481-1495.
13. Hammerschmidt, W., and Sugden, B. (1989). Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340, 393-397.
14. Hammerschmidt, W., Sugden, B., and Baichwal, V. R. (1989). The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J. Virol. 63, 2469-2475.
15. cdc2 activity. J. Virol. 69, 6705-6711.
16. Henderson, S., Rowe, M., Gregory, C., Wang, F., Kieff, E., and Rickinson, A. (1991). Induction of bcl-2 expression by Epstein-Barr virus Latent Membrane Protein-1 protects infected B cells from programmed cell death. Cell 65, 1107-1115.
17. Hori, M., Kamijo, R., Takeda, K., and Nagumo, M. (1994). Down-regulation of c-myc expression by Tumor Necrosis Factor-alpha in combination with Transforming Growth Factor-beta or Interferon-gamma with concomitant inhibition of proliferation in human cell-lines. J. Interferon Res. 14, 49-55.
18. Huen, D. S., Henderson, S. H., Croom-Carter, D., and Rowe, M. (1995). The Epstein-Barr virus Latent Membrane Protein (LMP1) mediates activation of NF-KB and cell surface phenotype via two effector regions in its carboxyl-terminal cytoplasmic domain. Oncogene 10, 549-560.
19. Kaye, K. M., Izumi, K. M., and Kieff, E. (1993). Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90, 9150-9154.
20. Laherty, C. D., Hu, H. M., Opipari, A. W., Wang, F., and Dixit, V. M. (1992). Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor KB. J. Biol. Chem. 267, 24157-24160.
21. Liebowitz, D., Mannick, J., Takada, K., and Kieff, E. (1992). Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B lymphocytes. J. Virol. 66, 4612-4616.
22. MacDonald, I., Wang, H., Grand, R., Armitage, R., Fanslow, W. C., Gregory, C. D., and Gordon, J. (1996). Transforming growth factor-β1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. Blood 87, 1147-1154.
23. Magrath, I., Jain, V., and Bhatia, K. (1992). Epstein-Barr virus and Burkitt's lymphoma. Sem. Cancer Biol. 3, 285-295.
24. Mann, K. P., and Thorley-Lawson, D. (1987). Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein. J. Virol. 61, 2100-2108.
25. Martin, J., Veis, D., Korsmeyer, S. J., and Sugden, B. (1993). Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J. Virol. 67, 5269-5278.
26. Menézes, J., Leibold, W., Klein, G., and Clements, G. (1975). Establishment and characterization of an EBV-negative B-lymphoma line, BJAB, from an exceptional EBV-genome-negative African Burkitt lymphoma. Biomedicine 22, 276-284.
27. Miller, W. E., Earp, H. S., and Raab-Traub, N. (1995). The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 69, 4390-4398.
28. Milner, A. E., Grand, R. J. A., and Gregory, C. D. (1995). Effects of interferon-α on human B cells: Repression of apoptosis and prevention of cell growth are independent responses of Burkitt lymphoma lines. Int. J. Cancer 61, 348-354.
29. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C., and Kieff, E. (1995). The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the Tumor Necrosis Factor receptor family. Cell 80, 389-399.
30. Okan, I., Wang, Y., Chen, F., Imreh, S., Klein, G., and Wiman, C. G. (1995). The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 11, 1027-1031.
31. Peng, M., and Lundgren, E. (1992). Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7, 1775-1782.
32. Peng, M., and Lundgren, E. (1993). Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T-cells and Hematopoietic cell lines: Cell-type-independent-induction of CD23, CD21, and ICAM-1. Leukemia 7, 104-112.
33. Robertson, E. S., and Kieff, E. D. (1995). Genetic analysis of Epstein-Barr virus in B lymphocytes. EBV Report 2, 73-80.
34. Rottleb, C., Bornkamm, G. W., and Polack, A. (1995). Among 17 inducers of differentiation only sodium-butyrate causes a permanent down-regulation of c-myc in Burkitt's lymphoma. Int. J. Cancer 62, 697-702.
35. Rowe, M. (1995). The EBV latent membrane protein-1 (LMP1): A tale of two functions. EBV Report 2, 99-104.
36. Rowe, M., Evans, H. S., Young, L. S., Hennessy, K., Kieff, E., and Rickinson, A. B. (1987). Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J. Gen. Virol. 68, 1575-1586.
37. Rowe, M., Khanna, R., Jacob, C. A., Argaet, V., Kelly, A., Powis, S., Belich, M., Croom-Carter, D., Lee, S., Burrows, S., Trowsdale, J., Moss, D. J., and Rickinson, A. B. (1995). Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein Barr Virus Latent Membrane protein-1: Coordinate upregulation of peptide transporters and HLA Class I antigen expression. Eur. J. Immunol. 25, 1374-1384.
38. Rowe, M., Lear, A., Croom-Carter, D., Davies, A. H., and Rickinson, A. B. (1992). Three pathways of Epstein-Barr virus (EBV) gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66, 122-131.
39. Rowe, M., Peng-Pilon, M., Huen, D. S., Hardy, R., Croom-Carter, D., Lundgren, E., and Rickinson, A. B. (1994). Upregulation of bcl-2 by the Epstein-Barr virus Latent Membrane Protein LMP1: A B-cell-specific response that is delayed relative to NF-KB activation and to induction of cell surface markers. J. Virol. 68, 5602-5612.
40. Rowe, M., Rooney, C. M., Rickinson, A. B., Lenoir, G. M., Rupani, H., Moss, D. J., Stein, H., and Epstein, M. A. (1985). Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int. J. Cancer 35, 435-441.
41. Shibuya, H., Yoneyama, M., Ninomiya-Tsuji, J., Matsumoto, K., and Taniguchi, T. (1992). IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signal pathways: Demonstration of a novel role for c-myc. Cell 70, 57-67.
42. 1 to Stransition, but not activation of human B lymphocytes. Exp. Cell Res. 171, 213-222.
43. Torsteinsdottir, S., Andersson, M. L., Avila-Carino, J., Ehlin-Henriksson, B., Masucci, M. G., Klein, G., and Klein, E. (1989). Reversion of tumorgenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int. J. Cancer 43, 273-278.
44. Uchanska-Ziegler, B., Schenk, A., Ziegler, A., Schendel, D. J., and Nossner, E. (1993). Soluble T-cell receptor-like properties of an HLA-B35-specific monoclonal antibody (Tü165). Eur. J. Immunol. 23, 734-738.
45. Wang, D., Liebowitz, D., and Kieff, E. (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831-840.
46. Wang, D., Liebowitz, D., Wang, F., Gregory, C., Rickinson, A., Larson, R., Springer, T., and Kieff, E. (1988). Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: Deletion of the amino terminus abolishes activity. J. Virol. 62, 4173-4184.
47. Wang, F., Gregory, C. D., Rowe, M., Rickinson, A. B., Wang, D., Birkenbach, M., Kikutani, H., Kishimoto, T., and Kieff, E. (1987). Epstein-Barr virus nuclear protein 2 specifically induces expression of the B cell activation antigen CD23. Proc. Natl. Acad. Sci. USA 84, 3452-3456.
48. Wang, F., Gregory, C. D., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. B., and Kieff, E. (1990a). Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64, 2309-2318.
49. Wang, F., Tsang, S.-F., Kurilla, M. G., Cohen, J. I., and Kieff, E. (1990b). Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64, 3407-3416.